Management of Acute Liver Failure

Created on Tue, 06/30/2015 - 17:42
Last updated on Fri, 06/22/2018 - 03:38

Management of acute liver failure seldom makes an appearance in the college exams, which makes some sense because there are only a few genuinely helpful strategies to deploy, and most of these are related either to reversal of some sort of toxicity (eg. paracetamol overdose) or the management of hepatic encephalopathy

The major influences on these lists of management options were the following papers:

Specific management

Usually we have very little to offer these people.

Obviously, the withdrawal of the hepatotoxic drug is a major specific step for the management of drug-induced hepatitis, but for the majority of other causes, there is no specific treatment -merely "wait-and-see". Ultimately, the last option is liver transplantation.

Broadly, the goals of therapy are:

  • Identify causes which might be potentially reversible
  • Maximise the chances of hepatic regeneration by supporting organ function
  • Identify the patients who are unlikely to survive supportive management (these need to be referred for urgent transplantation)

There are only a handful of conditions which have reliable treatment options beyond normal ICU support.

In brief summary:

Paracetamol overdose

N-acetylcystine

Wilson's disease (chronic)

Copper chelating agents

Hepatic vein thrombosis

Thrombolysis / clot retrieval;

TIPS procedure

Hepatitis viruses

Antiviral drugs

Autoimmune hepatitis

Steroids may be helpful... or may be harmful.

Alcoholic hepatitis

Steroids are probably helpful

Valproate overdose

L-carnitine, and probably also dialysis to extract the excess ammonia

Amanita phalloides

Haemopherfusion may remove the phallotoxins

Beyond this, all treatment is "supportive", i.e. there is nothing to be done for the primary cause of liver failure. One can merely stand by and correct all the various abnormalities which take place in the organism. The real definitive solution is transplantation, The EASL guidelines (2017) claim a survival of ~ 80% from this procedure.

Supportive management

Management plans should include the following points: 

  1.  Intubate the patient for airway protection, as they will be obtunded (and to control the CO2). The patient with fulminant liver failure is very likely to require intubation at some stage.
  2. Hyperventilation to low-normal PaCO2 (35 mmHg) is a part of HHHH therapy, and is mainly directed to prevent the cerebral vasodilation and intracranial hypertension which is associated with acute liver failure.
  3. Vasopressor support: Maintain haemodynamic stability using noradrenaline preferentially. These patients will vasodilate extensively. It will be important to avoid fluid overload because that tends to impair hepatic venous outflow.
  4. Sedation with short-acting drugs. Use propofol instead of benzodiazepines, and avoid long-acting opiates.
    Consider an ICP monitor. This offers you a means of monitoring the development of massive and undetected ICP fluctuations, presumably because you will react to them with more HHHH therapy. It is surprisingly safe - Rajajee et al (2017) trialled a protocol where all their acute liver patients got an ICP monitor and found that only one of the 24 had an intracranial haemorrhage (which was apparently asymptomatic and had "an excellent outcome"). All patients were given some Factor VIIa no more than 1hr prior to the procedure, and they all used delicate little intraparenchymal monitors rather than EVDs.
    Management of raised ICP for these patients does not differ significantly from what you'd normally do for stroke or TBI. If the ICP is uncontrollable by normal means, various extreme authors have suggested various extreme measures. Ringe et al (1988) found that the dying liver was causing more harm than good, and removed it entirely ("we considered it a potential advantage to tolerate a prolonged anhepatic period before implantation of a functioning allograft than to leave the necrotic liver in situ")
  5. Hypothermia to a temperature of 32-33° - 
    Hypernatremia (to control ICP, with hypertonic saline) to achieve a sodium of 145-155 mmol/L
    Replace phosphate: hypophosphataemia tends to develop in the recovery phase, as hepatocytes reproduce vigorously. As a major intracellular anion, phosphate will be sucked up into the rapidly growing cells. Also you need it to make use of all that glucose you are infusing. In summary, give phosphate.
  6. Haemodiafiltration - continuously - to remove ammonia. This prevents acute cerebral oedema. In hyperacute liver failure cerebral oedema may actually develop before hepatic encephalopathy or other major complications of liver failure. Don't use citrate.
    Fluid resuscitation with crystalloid - keeping in mind that fluid overload is undesirable. EASL guidelines (2017) recommend something buffered with acetate.
  7. Give 10-50% dextrose as infusion. Anticipate hypoglycaemia and increased resting energy expenditure. Caloric requirements are  increased by 18 to 30% compared with normal controls (Schneeweiss, 1992) and there does not seem to be any special increase the the metabolism of any specific macronutrient group. The authors of that 1992 study estimated that normal hepatic glucose release  rate is about 8μmol/kg/min, and so one should aim to duplicate this with exogenous glucose in the anhepatic patient. That ends up being about 6-7g/hr of dextrose for a 70kg patient, or approximately 125-150ml/hr of 5% dextrose.
    Think about enteral lactulose for management of hepatic encephalopathy, though it is somewhat controversial. Lactulose in acute liver failure is only described as "possibly helpful" by the AASLD statement (Polson et al, 2005) and is not recommended by Stravitz et al (2007). There is no evidence that it improves survival in acute liver failure, and it may distend the gut, causing aspiration and obscuring the operative field during the liver transplant. Bernal & Wendon (2013) described it as dangerous, whereas others defended its use in resource-poor environments where liver transplantation will not be an option.
    Ensure PPIs are administered. Don't give them any excuse to have a GI bleed.
    Drain the tense ascites. It behaves like a gravid uterus, from a haemodynamic standpoint. If there is tense ascites, draining it could potentially improve venous return and haemodynamics.
  8. Anticipate coagulopathy.
    Administer Vitamin K empirically, however little that is expected to have. Apparently the correct dose is 10mg. Pereira et al (2005) gave this dose to their patients and found that 27% had some sort of subclinical Vitamin K deficiency. Hard to say whether this had any positive effect on their INRs, let alone survival
    Consider blood products, but view complete correction as unobtainable.
    Remember: in spite of apparent "numerical" coagulopathy, a hypercoagulable state develops.
  9. Vigilant surveillance for sepsis: they are prone to it, and it makes the encephalopathy worse. The EASL guidelines (2017) recommend daily surveillance cultures.

As raised by some of the readers, lactulose in acute liver failure is something of a polarising issue here. 

 

References

Chapter 44   (pp. 501) Liver  failure by Christopher  Willars  and  Julia  Wendon

Daly, Frank FS, et al. "Guidelines for the management of paracetamol poisoning in Australia and New Zealand-explanation and elaboration." Medical journal of Australia 188.5 (2008): 296.

Bailey, Benoit, René Blais, and Anne Letarte. "Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death." Annals of emergency medicine 44.4 (2004): 401-406.

Parsons-Smith, B. G., et al. "The electroencephalograph in liver disease." The Lancet 270.7001 (1957): 867-871.

Ramos, Juan Francisco Rivera, and Celina Rodríguez Leal. "Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy." Ann Hepatol 10 (2011): S36-S39.

Walsh, Timothy S., et al. "Energy expenditure in acetaminophen-induced fulminant hepatic failure." Critical care medicine 28.3 (2000): 649-654.

Ichai, Philippe, et al. "Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis." Liver transplantation 13.7 (2007): 996-1003.

O’Grady, John G., et al. "Early indicators of prognosis in fulminant hepatic failure." Gastroenterology 97.2 (1989): 439-445.

Dhiman, Radha K., et al. "Early indicators of prognosis in fulminant hepatic failure: An assessment of the Model for End‐Stage Liver Disease (MELD) and King's College Hospital Criteria." Liver transplantation 13.6 (2007): 814-821.

Yantorno, Silvina E., et al. "MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure." Liver transplantation13.6 (2007): 822-828.

Wiesner, Russell, et al. "Model for end-stage liver disease (MELD) and allocation of donor livers." Gastroenterology 124.1 (2003): 91-96.

Gleisner, Ana L., et al. "Survival benefit of liver transplantation and the effect of underlying liver disease." Surgery 147.3 (2010): 392-404.

Lee, William M., Anne M. Larson, and R. Todd Stravitz. "AASLD position paper: the management of acute liver failure: update 2011." Hepatology 55 (2011): 965-967.

Ding, G. K. A., and N. A. Buckley. "Evidence and consequences of spectrum bias in studies of criteria for liver transplant in paracetamol hepatotoxicity." QJM101.9 (2008): 723-729.

Lee, William M., R. Todd Stravitz, and Anne M. Larson. "Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011." Hepatology 55.3 (2012): 965-967.

McPhail, Mark JW, Julia A. Wendon, and William Bernal. "Meta-analysis of performance of Kings’s College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure." Journal of hepatology 53.3 (2010): 492-499.

Stravitz, R. Todd, et al. "Intensive care of patients with acute liver failure: recommendations of the US Acute Liver Failure Study Group." Critical care medicine 35.11 (2007): 2498-2508.

Warrillow, S. J., and R. Bellomo. "Preventing cerebral oedema in acute liver failure: the case for quadruple-H therapy." Anaesthesia and intensive care 42.1 (2014): 78.

Auzinger, Georg, and Julia Wendon. "Intensive care management of acute liver failure." Current opinion in critical care 14.2 (2008): 179-188.

Warrillow, S., and R. Bellomo. "Intensive Care Management of Severe Acute Liver Failure." Annual Update in Intensive Care and Emergency Medicine 2015. Springer International Publishing, 2015. 415-430.

European Association for the Study of the Liver. "EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure." Journal of Hepatology 66.5 (2017): 1047-1081.

Flamm, Steven L., et al. "American Gastroenterological Association Institute Guidelines for the Diagnosis and Management of Acute Liver Failure.Gastroenterology 152.3 (2017): 644-647.

Schneeweiss, Bruno, et al. "Energy metabolism in acute hepatic failure." Gastroenterology 105.5 (1993): 1515-1521.

Rajajee, Venkatakrishna, et al. "Protocol based invasive intracranial pressure monitoring in acute liver failure: feasibility, safety and impact on management." Critical Care21.1 (2017): 178.

Ringe, B., et al. "Total hepatectomy as temporary approach to acute hepatic or primary graft failure." Transplantation proceedings. Vol. 20. No. 1 Suppl 1. 1988.

Pereira, Stephen P., et al. "Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K 1) in severe acute liver disease." Journal of hepatology 42.3 (2005): 365-370.

Polson, Julie, and William M. Lee. "AASLD position paper: the management of acute liver failure." Hepatology 41.5 (2005): 1179-1197.

Stravitz, R. Todd, et al. "Intensive care of patients with acute liver failure: recommendations of the US Acute Liver Failure Study Group." Critical care medicine 35.11 (2007): 2498-2508.

Bernal, William, and Julia Wendon. "Acute liver failure." New England Journal of Medicine 369.26 (2013): 2525-2534.